Want to see CGEM full AI Analyst Report?
CGEM Stock Chart & Stats
$22.60
-$0.18(-1.04%)
At close: 4:00 PM EDT
$22.60
-$0.18(-1.04%)
Day’s Range― - ―
52-Week Range$5.68 - $23.19
Previous CloseN/A
Volume316.66K
Average Volume (3M)634.54K
Market Cap
$1.40B
Enterprise Value$796.04
Total Cash (Recent Filing)$334.54M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 05, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding64,354,690
10 Day Avg. Volume656,804
30 Day Avg. Volume634,541
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.11Price Target Upside50.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$13.55M
Bulls Say, Bears Say
Bulls Say
Phase 3 Oncology MilestoneThe Phase 3 result materially strengthens zipalertinib’s regulatory path in EGFR exon 20 insertion NSCLC. A potential first-line approval could create a commercial foundation and improve Cullinan’s competitive position in a genetically defined market.
Diversified Clinical PipelineEarly autoimmune data broaden the company beyond a single oncology program and support development of a potential T cell engager franchise. Expansion into lupus, rheumatoid arthritis and autoimmune cytopenias provides longer-term pipeline optionality.
Very Low Financial LeverageMinimal debt reduces fixed financial obligations and limits solvency pressure while clinical programs advance. This gives management greater flexibility to allocate capital toward development, regulatory work and potential commercialization rather than debt service.
Bears Say
Pre-commercial Business ModelThe absence of meaningful recurring revenue leaves Cullinan dependent on clinical success, partnerships or future financing. Until a program reaches commercialization, operating performance will remain highly sensitive to trial outcomes and capital availability.
Persistent Cash BurnSustained cash outflows place ongoing pressure on the company’s runway and may require spending reductions, partnering or capital raising. Heavy investment is typical for biotech, but the burn remains a structural risk before product revenue begins.
Capital Base ErosionThe shrinking equity base indicates that accumulated losses are consuming shareholder capital rather than building financial resources. Continued erosion could reduce flexibility for funding multiple programs and increase dependence on external financing or strategic transactions.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $23.19 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $1.40B.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Nov 05, 2026 which is in 63 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Aug 06, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.011.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.85.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 64,354,690 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 1.931%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.11 (50.93% Upside)
$34.11 (50.93% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 171.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cullinan Management
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Stock 12 Month Forecast
Average Price Target
$34.11
▲(50.93% Upside)
Technical Analysis
Ownership Overview
15.76% Insiders
11.20% Mutual Funds
23.01% Other Institutional Investors
31.33% Public Companies and Individual Investors